GL Capital Group, led by former Novartis China head Jeffrey Li, has so far raised $162.5 million for its fourth USD-denominated private equity fund dedicated to investing in China’s healthcare industry, according to its filing with the US Securities and Exchange Commission (SEC) on Wednesday.
The new fund, GL China Opportunities Fund IV LP, has garnered capital commitment from 17 limited partners (LPs), as of December 20, according to the filing. The firm did not disclose the fund’s target size.
SEC filings typically reflect the amount raised from only US investors.
